Neuburgh Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | $169K | Hold |
2,992
| – | – | 0.01% | 712 |
|
|
2019
Q2 | $166K | Hold |
2,992
| – | – | 0.01% | 725 |
|
|
2019
Q1 | $151K | Hold |
2,992
| – | – | 0.01% | 728 |
|
|
2018
Q4 | $121K | Buy |
2,992
+578
| +24% | +$23.4K | ﹤0.01% | 740 |
|
|
2018
Q3 | $167K | Buy |
2,414
+204
| +9% | +$14.1K | 0.01% | 729 |
|
|
2018
Q2 | $167K | Hold |
2,210
| – | – | 0.01% | 694 |
|
|
2018
Q1 | $117K | Buy |
2,210
+374
| +20% | +$19.8K | ﹤0.01% | 763 |
|
|
2017
Q4 | $98K | Buy |
1,836
+340
| +23% | +$18.1K | ﹤0.01% | 793 |
|
|
2017
Q3 | $89K | Buy |
1,496
+442
| +42% | +$26.3K | ﹤0.01% | 781 |
|
|
2017
Q2 | $83K | Buy |
1,054
+578
| +121% | +$45.5K | ﹤0.01% | 768 |
|
|
2017
Q1 | $39K | Buy |
+476
| New | +$39K | ﹤0.01% | 804 |
|